Sandra Eayrs - Nuwellis Chief Officer
| NUWE Stock | USD 1.17 0.04 3.31% |
Insider
Sandra Eayrs is Chief Officer of Nuwellis
| Address | 12988 Valley View Road, Eden Prairie, MN, United States, 55344 |
| Phone | 952 345 4200 |
| Web | https://www.nuwellis.com |
Nuwellis Management Efficiency
The company has return on total asset (ROA) of (0.7949) % which means that it has lost $0.7949 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.8745) %, meaning that it created substantial loss on money invested by shareholders. Nuwellis' management efficiency ratios could be used to measure how well Nuwellis manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -2.17. In addition to that, Return On Capital Employed is expected to decline to -2.81. At present, Nuwellis' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 14.2 M, whereas Other Current Assets are forecasted to decline to about 254 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Knudson | ReShape Lifesciences | 75 | |
| Jason Cook | Bluejay Diagnostics | 42 | |
| Antonella MD | Helius Medical Technologies | 57 | |
| CPA CPA | NanoVibronix | 68 | |
| DVM DVM | ReShape Lifesciences | N/A | |
| Mark Feinberg | Bluejay Diagnostics | N/A | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Lawrence Picciano | Helius Medical Technologies | N/A | |
| JD MBA | SINTX Technologies | 60 | |
| Danielle Watson | Heart Test Laboratories | 42 | |
| Harold MD | NanoVibronix | 70 | |
| Jody Dahlman | ReShape Lifesciences | N/A | |
| Kenneth CPA | Bluejay Diagnostics | 44 | |
| Katherine Tweden | ReShape Lifesciences | 63 | |
| Mark MD | Bluejay Diagnostics | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| Kevin Vance | Bluejay Diagnostics | 66 | |
| Richard Ginn | Tenon Medical | 58 | |
| CPA CPA | Helius Medical Technologies | 63 | |
Management Performance
| Return On Equity | -9.87 | ||||
| Return On Asset | -0.79 |
Nuwellis Leadership Team
Elected by the shareholders, the Nuwellis' board of directors comprises two types of representatives: Nuwellis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuwellis. The board's role is to monitor Nuwellis' management team and ensure that shareholders' interests are well served. Nuwellis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuwellis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Scott, Chief Officer | ||
| Neil Esq, General VP | ||
| FACC MD, Chief Board | ||
| Sandra Eayrs, Chief Officer | ||
| Laurent Duhoux, VP Devel | ||
| Paul Wotta, Corporate Controller | ||
| Vitaliy Epshteyn, Vice Engineering | ||
| John Kowalczyk, Senior Marketing | ||
| Rob Scott, Director Officer | ||
| William MD, VP Marketing | ||
| FACC MBA, Chief Board | ||
| Nestor Jaramillo, CEO President |
Nuwellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuwellis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.87 | ||||
| Return On Asset | -0.79 | ||||
| Profit Margin | (2.32) % | ||||
| Operating Margin | (1.06) % | ||||
| Current Valuation | 3.99 M | ||||
| Shares Outstanding | 4.37 M | ||||
| Shares Owned By Insiders | 1.60 % | ||||
| Shares Owned By Institutions | 1.40 % | ||||
| Number Of Shares Shorted | 322.41 K | ||||
| Price To Book | 1.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Nuwellis is a strong investment it is important to analyze Nuwellis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nuwellis' future performance. For an informed investment choice regarding Nuwellis Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuwellis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Nuwellis Stock refer to our How to Trade Nuwellis Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuwellis. If investors know Nuwellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuwellis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (60.77) | Revenue Per Share 48.483 | Quarterly Revenue Growth 0.057 | Return On Assets (0.79) | Return On Equity (9.87) |
The market value of Nuwellis is measured differently than its book value, which is the value of Nuwellis that is recorded on the company's balance sheet. Investors also form their own opinion of Nuwellis' value that differs from its market value or its book value, called intrinsic value, which is Nuwellis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuwellis' market value can be influenced by many factors that don't directly affect Nuwellis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuwellis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuwellis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuwellis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.